These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 28792635)

  • 1. Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment.
    Okada M; Watarai Y; Iwasaki K; Murotani K; Futamura K; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Narumi S; Takeda A; Morozumi K; Uchida K; Kobayashi T
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28792635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
    Sugiyama K; Hyodo Y; Aikawa A
    Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
    Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
    PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
    Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
    Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
    Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
    Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T
    Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period.
    Kohei N; Hirai T; Omoto K; Ishida H; Tanabe K
    Am J Transplant; 2012 Feb; 12(2):469-76. PubMed ID: 22054413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High B-cell activating factor is not associated with worse 3-year graft outcome in blood group-incompatible kidney transplantation with rituximab induction.
    Lehnhardt AM; Strecker M; Eiermann T; Marget M; Thaiss F; Nashan B; Koch M
    Clin Transplant; 2015 Apr; 29(4):359-64. PubMed ID: 25627801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation.
    Koch M; Wiech T; Marget M; Peine S; Thude H; Achilles EG; Fischer L; Lehnhardt A; Thaiss F; Nashan B
    Clin Transplant; 2015 Nov; 29(11):1021-8. PubMed ID: 26333844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
    Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K
    Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
    Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
    Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation.
    Nakao T; Ushigome H; Kawai K; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
    Transplant Proc; 2015 Apr; 47(3):644-8. PubMed ID: 25891703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
    Han S; Hwang E; Park S; Park U; Kim H; Cho W
    Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy.
    Saito K; Nakagawa Y; Suwa M; Kumagai N; Tanikawa T; Nishiyama T; Ueno M; Gejyo F; Nishi S; Takahashi K
    Xenotransplantation; 2006 Mar; 13(2):111-7. PubMed ID: 16623803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABO-incompatible pediatric kidney transplantation without antibody removal.
    Kawamura T; Hamasaki Y; Takahashi Y; Hashimoto J; Kubota M; Muramatu M; Itabashi Y; Hyodo Y; Ohashi Y; Aikawa A; Sakai K; Shishido S
    Pediatr Nephrol; 2020 Jan; 35(1):95-102. PubMed ID: 31673829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desensitization with the Use of an Antibody Removal-Free Protocol in ABO-Incompatible Kidney Transplant Recipients with a Low Anti-A/B Antibody Titer.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018 May; 50(4):982-986. PubMed ID: 29731097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report.
    Nishimura H; Yamada Y; Hisano S; Mitsuke A; Tatarano S; Gotanda T; Hayami H; Nakagawa M; Enokida H
    BMC Nephrol; 2018 Oct; 19(1):254. PubMed ID: 30290778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.
    Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M
    Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABO-incompatible kidney transplantation: long-term outcomes.
    Tanabe K; Ishida H; Inui M; Okumi M; Shirakawa H; Shimizu T; Omoto K; Kondo T
    Clin Transpl; 2013; ():307-12. PubMed ID: 25095522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABO-incompatible kidney transplantation.
    Takahashi K; Saito K
    Transplant Rev (Orlando); 2013 Jan; 27(1):1-8. PubMed ID: 22902167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.